Skip to content

Rock the World for ALS

Rock the World for ALS

Where the Money Goes

Canadian Research. Worldwide Hope.

Rock the World for ALS is more than a community art campaign. It’s an opportunity to bring people together and financially support the search for better ALS treatments.

Our fundraising efforts are intended to support Borotherapeutics Ltd., a Canadian biotechnology company based in Winnipeg, Manitoba.

Our fundraising goal

$15,000 CAD

$0 raised · 0% of goal

Raised so far
$0
Processing fees
$0
Transferred to Borotherapeutics
$0
Last updated
Not updated yet

These figures are entered and verified manually by the campaign organizer. They are not a live feed from Buy Me a Coffee.

Our campaign goal

$15,000 CAD

Raised through Rock the World for ALS to help fund the preliminary regulatory steps toward human clinical trials.

Borotherapeutics’ full development budget

Over $3 million USD

The complete program — drug formulation, chemical manufacturing, and safety and toxicology studies.

About Borotherapeutics

Originating from the University of Manitoba’s College of Pharmacy, Borotherapeutics develops boron-based therapies for neurodegenerative diseases, particularly ALS.

Its leading experimental drug candidate, Borsantrazole™, has shown encouraging results in preclinical ALS mouse studies, including:

  • Delayed disease onset.
  • Prevention of disease-related weight loss.
  • Extended survival.

The company’s objective is to advance this research toward human clinical trials.

Borsantrazole remains experimental and has not yet been proven safe or effective in humans.

Meet the Borotherapeutics Team

Borsantrazole is being developed by two researchers working together in Winnipeg, Manitoba.

Dr. Geoffrey K. Tranmer

Co-founder

University of Manitoba professor and researcher leading the development of innovative therapeutic approaches to ALS.

Dr. Nitesh Sanghai

Co-founder

Medicinal chemistry and neuroscience researcher, ALS advocate and co-inventor of Borsantrazole. Recipient of the 2025 Mitacs Outstanding Innovation Award.

Research in Action

The Borotherapeutics team working in the laboratory, developing an experimental drug candidate for ALS.

Celebrating Research Excellence

Celebrating Dr. Nitesh Sanghai's Distinguished Dissertation Award from the University of Manitoba.

Dr. Geoffrey K. Tranmer · Dr. Nitesh Sanghai

Our $15,000 Fundraising Goal

Helping Take the Next Step Toward Human Clinical Trials

Borotherapeutics has developed an experimental ALS drug candidate called Borsantrazole (BSZ), which has demonstrated encouraging preliminary results.

The company is now preparing for the next stage of drug development, with the ultimate objective of initiating Phase 1 human clinical trials.

The complete development plan includes drug formulation, chemical manufacturing and essential safety and toxicology studies, with an estimated budget exceeding $3 million USD.

How Your Contributions Will Help

Through Rock the World for ALS, our goal is to raise $15,000 CAD to help Borotherapeutics fund:

  • Preliminary regulatory meetings with the U.S. Food and Drug Administration (FDA).
  • Preliminary regulatory meetings with Health Canada.
  • Preparation and filing of an FDA Orphan Drug Designation application.

Orphan Drug Designation can provide important financial and regulatory incentives that help companies develop treatments for rare diseases such as ALS.

Borotherapeutics is also committed to pursuing a patient-informed approach, incorporating the needs of people living with ALS throughout the drug development process.

To date, the company has received no outside investment, according to its founders. Its preliminary research has been supported through personal funds and government research grants through the University of Manitoba.

Our $15,000 campaign will help support important preliminary regulatory steps on the path toward human clinical trials.

$15,000 may be a small part of a much larger journey, but every journey needs a first step.

Every rock matters. Every coffee counts.

For those of us living with ALS, time is something we cannot afford to waste.

Research and recognition

  • $730,576 in research funding

    Five-year Canadian Institutes of Health Research funding awarded to the founders’ ALS drug development project.

  • 2025 Mitacs Outstanding Innovation Award

    Recognizing the innovation behind the Borsantrazole research program.

  • Peer-reviewed scientific research

    Findings have been published and reviewed within the scientific community.

  • International ALS research conferences

    The team has presented its work to ALS researchers around the world.

Research in Action

Follow the people, discoveries and progress behind the research we are working to support.

Featured peer-reviewed publication

The Development of Borsantrazole

View Borotherapeutics’ most recent peer-reviewed publication in Advanced Science on the development of ALS drug candidate Borsantrazole.

Read the Scientific Publication

Research updates will appear here as the project progresses. Photographs, articles and milestones are published by the campaign organizer.

Optional financial support

Contributions are received by the campaign organizer for the intended support of Borotherapeutics, a for-profit biotechnology company. Taking part in the campaign — painting, uploading, liking and sharing a rock — is free and never requires a contribution.

The coffee window opens right here on this page — you never leave the site.

Financial contributions are voluntary and are not eligible for charitable donation tax receipts. Borotherapeutics is not a registered charity.

Learn more